BridgeBio Oncology Therapeutics, Inc. Proceeds from Issuance of Private Placement
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Proceeds from Issuance of Private Placement of $373.46 million for the 12-month period ending 2025-12-31, per its POS AM filed 2026-04-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-04-30
- BridgeBio Oncology Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2025-12-31 was $0.00.
- BridgeBio Oncology Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2024-12-31 was $0.00.
- BridgeBio Oncology Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2024-09-30 was -$5.09M.
- BridgeBio Oncology Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2024-06-30 was $0.00.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 9 month as first filed | Proceeds from Issuance of Private Placement 12 month | Proceeds from Issuance of Private Placement 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $373.46M POS AM · filed 2026-04-30 | ||||
| 2025-09-30 | $373.46M 10-Q · filed 2025-11-12 | |||||
| 2024-12-31 | $0.00 derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | -$5.09M derived: sum of 2 quarters · filed 2026-04-30 | -$5.09M derived: sum of 3 quarters · filed 2026-04-30 | $0.00 POS AM · filed 2026-04-30 | $5.09M 10-K · filed 2025-03-11 | |
| 2024-09-30 | -$5.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$5.09M derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $5.09M 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $5.09M 10-Q · filed 2025-08-01 | ||||
| 2024-03-31 | $5.09M 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |